

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Ponni Subbiah, M.D.		
2. Your Title: Chief Medical Officer		
3. The Entity(ies) You are Representing: Indivior PLC		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No x
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.		
<ul style="list-style-type: none">- Federal Supply Schedule (FSS) contract for Veterans Administration, Indian Health Services, Coast Guard, and Department of Defense- Defense Health Administration/TRICARE- Health Resources and Services Administration (HRSA/340B) - <i>Medicaid Rebate Agreements with the states</i>- <i>Various arrangements with foreign governments</i>		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: 

Date: 2/26/2018

PONNI SUBBIAH, MD, MPH

SUMMARY: Neurologist with over nineteen years of experience in the pharmaceutical industry and global health sector with in-depth expertise in drug development, clinical research, and global medical affairs. Supervised the development and execution of medical and clinical research strategies in various therapeutic areas, including addiction, oncology, neurology, psychiatry, pain, diabetes, inflammation, urology, respiratory, and infectious diseases. Strong strategic and communication skills with proficiency in interacting with various stakeholders including scientific thought leaders, investigators, regulators, and media.

PROFESSIONAL EXPERIENCE

CHIEF MEDICAL OFFICER, INDIVIOR PLC **Oct 2016-Present**
RICHMOND, VA

Responsible for strategic and operational leadership of pharmacovigilance and medical affairs, including scientific publications, medical information, medical education and communication, and post-approval data generation.

VICE PRESIDENT, CLINICAL DEVELOPMENT, REVANCE THERAPEUTICS, INC. **July-Aug 2016**
NEWARK, CA

Lead the phase II / III clinical development program assessing the efficacy and safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia; Establish the Medical Affairs group, which will support both the therapeutic and aesthetic programs.

PRINCIPAL AND FOUNDER, GLOBAL MED STRATEGIES, LLC **2014-2016**
SAN FRANCISCO, CA

Provide consulting services for the life sciences industry and non-profit health sector, which includes both advisory services and hands-on support in the areas of global medical affairs, product development strategy, clinical trial design and management, and global access strategies. Clients include Astellas, Actelion, Boehringer Ingelheim, and Critical Path Institute.

GLOBAL PROGRAM LEADER, DRUG DEVELOPMENT, PATH **2012-2014**
SOUTH SAN FRANCISCO, CA

Directed PATH's drug development program with focus on the discovery and development of safe, effective, and affordable treatments for neglected diseases in the developing world, including in diarrheal/enteric diseases, HIV Pre-Exposure Prophylaxis (PrEP), and visceral leishmaniasis.

PFIZER, INC, NEW YORK, NY

Vice President, Global Access, Emerging Markets Business Unit **2008-2011**

Developed strategy and execution of new corporate mission to improve healthcare access for low-income populations in developing world through approaches that were commercially viable and sustainable. Established innovative partnerships (Grameen, Vodafone, Clinton Foundation) and supervised execution of 5 unique pilots with metrics. Supervised optimization of complex oncology access program in 8 Asian and 2 African countries.

Vice President, Global Medical Affairs (Urology/Respiratory); US Medical Affairs **2005-2008**
(Alzheimer's Disease/Neuroscience, Arthritis, Metabolism, Pain)

Provided strategic direction and medical management for inline and peri-launch products in areas of Smoking Cessation, COPD, Overactive Bladder, Erectile Dysfunction, Inflammation, Alzheimer's Disease, Pain, Epilepsy, Depression, Schizophrenia, and Multiple Sclerosis. Included major drug franchises: Viagra, Detrol, Toviaz, Chantix, Spiriva, Celebrex, Aricept, Rebif, Geodon, Zoloft. As company medical spokesperson, effectively responded to media and public inquiries related to products in portfolio (e.g. Good Morning America, Squawk Box, congressional hearing).

Sr Medical Director/Group Leader, US Medical Affairs: Neurology, Diversified Products **2003-2005**

Supervised development and implementation of medical and clinical research strategies for Neurology Patented Portfolio and Diversified Products Portfolio (over 100 brands in later part of lifecycle).

Director of Medical Affairs, Latin America, Emerging Markets **2002-2003**
Through collaboration with country affiliates, supervised development/implementation of regional medical, clinical research, and regulatory strategies that were aligned with global and local business goals.

Medical Director / Team Leader, Global Medical Affairs, Alzheimer's (Aricept) Team **1996-2002**
Led key clinical trials that extended approval for use in more advanced Alzheimer's disease and for longer duration. Supervised implementation of global medical strategies and lifecycle plan

OTHER EXPERIENCES

Clinical Instructor / Staff Neurologist and Electroencephalographer **1994-1996**
University of CA, San Francisco, Fresno Medical Education Program, VA Medical Center, Fresno, CA

Staff Neurologist, Alzheimer's Disease Center of Central California, Fresno, CA **1994-1995**

POSTDOCTORAL TRAINING

Clinical and Research Fellowships
Research/Clinical Fellowship in AIDS Neurology, Johns Hopkins Univ School of Medicine, Baltimore, MD

Internships and Residencies
Neurology, Mayo Graduate School of Medicine, Rochester, MN
Internal Medicine, Mayo Graduate School of Medicine, Rochester, MN
Internal Medicine, Howard University Hospital, Washington, D.C.

EDUCATION

Master of Public Health, Johns Hopkins Bloomberg School of Public Health
Doctor of Medicine, Madras Medical College, Madras, India

PROFESSIONAL LICENSURE

New York Medical License Registration

BOARD MEMBERSHIP

Member, Board of Directors, Association for Accreditation for Human Research Protection Programs, Inc. (AAHRPP)

BIBLIOGRAPHY

Original Reports

- **Subbiah P**, Wijdicks E, Muentner M, et al. Skin lesion with a fatal neurologic outcome (Degos' disease). *Neurology* 1996;46:636-640.
- **Subbiah P**, Mouton P, Fedor H, McArthur J, Glass J. Stereological analysis of cerebral atrophy in Human Immunodeficiency Virus-associated dementia. *Journal of Neuropathology and Experimental Neurology* 1996;55:1032-7.
- Feldman H, Gauthier S, Hecker J, Vellas B, **Subbiah P**, Whalen E, The Donepezil MSAD Study Investigators Group. A 24-week, randomized, double blind study of donepezil in moderate to severe Alzheimer's disease. *Neurology* 2001;57:613-621.
- Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm A-L, Zhang R, Haglund A, **Subbiah P**, The Donepezil Nordic Study group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology* 2001; 57:489-496
- Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, **Subbiah P**. Functional, cognitive and behavioral benefits of donepezil in patients with moderate Alzheimer's disease. *Curr Med Res Opin.* 2002;18:347-354.
- Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, **Subbiah P**, Whalen E, Emir B, The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. *Int Psychogeriatr.* 2002;14:389-404.
- Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm A-L, Mastey V, Haglund A, Zhang R, Miceli R, Chin W, **Subbiah P**. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double blind, randomized trial. *Dement Geriatr Cogn Disord.* 2003;15:44-54.
- Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, **Subbiah P**, The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease, and the impact on caregiver burden. *J Am Geriatr Soc.* 2003.
- Gomez-Perez F, Perez-Monteverde A, Nascimento O, Aschner P, Tagle M, Fichtner K, **Subbiah P**, Mutisya E, Parsons B for the Latin American Diabetic Neuropathy Study Group. Gabapentin for the treatment of painful diabetic neuropathy: dosing to achieve optimal clinical response. *Br J Diabetes Vasc Dis* 2004; 4:173-8

Book Chapters

- Waldemar G, Winblad B, **Subbiah P**. Benefits of donepezil on cognition, function, and/or neuropsychiatry symptoms in patients with mild and moderate Alzheimer's disease over one year. In: Iqbal K, Sisodia SS, Winblad B (eds) *Alzheimer's disease: Advances in Etiology, Pathogenesis and Therapeutics*. John Wiley & Sons, 2001, pp 725-738.
- Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, **Subbiah P**. The efficacy and safety of donepezil in patients with moderate to severe Alzheimer's disease. In: Vellas B et al.(eds) *Research and Practice in Alzheimer's Disease*. Volume 6. New York: Springer Publishing Company, 2002, pp302–307.

Abstracts and Presentations

- Johannsen P, Barcikowska M, Hasselbalch S, Ihl R, Karageorgiou C, Nunez M, Salmon E, Trixler M, Qvitzau S, Johansen L, Emir B, **Subbiah P**, and The AWARE Study Group. Results from the pre-randomization phase of the donepezil AWARE study: further understanding the meaning of "clinical benefit". Poster presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, 3-6 April 2002, Geneva, Switzerland.
- Ihl R, Jakobsen S, Kloszewska I, Lambert M, Sakka V, Tilker H, Tury F, Verhey FRJ, Johansen L, Emir B, **Subbiah P**, Johannsen P, The AWARE Study Group. Further understanding the meaning of "clinical benefit": results from the pre-randomization phase of the donepezil AWARE study. *Eur Neuropsychopharmacol.* 2002;12(Suppl 3):S385(P.4.042).
- Tsolaki M, Dautzenberg P, Hampel H, Jakab G, Kozubski W, Lauritzen L, McCarthy J, Salmon E, Johansen L, Kumar N, Emir B, **Subbiah P**, Johannsen P. Further understanding the meaning of

“clinical benefit”: results from the pre-randomization phase of the donepezil AWARE study. *Eur J Neurol.* 2002; 9(Suppl 2): 191:(P3111).

- Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Emir B, **Subbiah P**, Mastey V. Differences in Alzheimer's disease resource utilization across countries does not preclude pooling data in a multinational trial. *J Neurol.* 2002; 249(Suppl 1): 1-224.
- Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, **Subbiah P**. Donepezil treatment benefits caregivers of patients with moderate to severe Alzheimer's disease (AD). *Eur J Neurol.* 2002; 9(Suppl 2): 34:(SC228).
- Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, **Subbiah P**. Functional, cognitive and behavioral benefits of donepezil in patients with moderate Alzheimer's disease. *J Am Geriatr Soc.* 2002; 50(Suppl 4): S1-204.
- Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Emir B, **Subbiah P**, Mastey V. Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits. *Neurobiology Aging.* 2002; 23(1S): 285.
- Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, **Subbiah P**. Exploratory analysis of the effects of donepezil in moderate and severe Alzheimer's disease patients. *Neurobiology Aging.* 2002;23(1S):277.